Krystal Biotech Inc reports results for the quarter ended in December - Earnings Summary

Krystal Biotech

27/02/2023 14:33

* Krystal Biotech Inc  KRYS.OQ  reported a quarterly
adjusted loss
of $1.25​​ per share for the quarter ended in December. The mean
expectation of seven analysts for the quarter was for a loss of
$1.32 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Krystal Biotech Inc's reported EPS for the quarter was a
loss of
$1.25​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Krystal Biotech Inc shares had fallen by 1.0% this
quarter.
    * The company reported a quarterly loss of $32.05 million.
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $106.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
27 at 02:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -1.32          -1.25          Beat
 Sep. 30 2022      -1.22          -1.17          Beat
 Jun. 30 2022      -1.02          -1.10          Missed
 Mar. 31 2022      -1.05          -0.99          Beat